AstraZeneca Plc - Enterprise Tech Ecosystem Series
AstraZeneca Plc (AstraZeneca) is a developer, manufacturer, and marketer of prescription pharmaceuticals. The company provides drugs for various therapeutic areas, including oncology, cardiovascular, renal, and metabolic disease (CVRM), respiratory, and others. AstraZeneca markets its products under various brand names including Byetta, Casodex, Faslodex, Zoladex, Tagrisso, Iressa, Symbicort, Pulmicort, Lynparza, Nexium, Onglyza, etc. The company sells its products to specialty care and primary care physicians through wholly-owned local marketing companies, local representative offices and distributors. It has business presence across the Americas, Africa, Europe, and Asia.
AstraZeneca operates R&D and innovation centers, in-house labs, and healthcare ecosystems in China.
In-house Labs and Innovation Center: AstraZeneca is focusing on building a digital factory of the future by testing and creating integrated solutions in its in-house labs. The technology focus of its in-house labs includes image recognition, AI, electronic records, digital twins, robotics, and automation. AstraZeneca operates Healthcare IoT Innovation Center in China responsible for developing development of smart healthcare solutions to improve patient experience. It also operates an in-house incubation lab for developing integrated augmented reality (AR), AI, and predictive maintenance solutions for internal operations optimization.
In November 2019, AstraZeneca announced creation of a Global R&D Center, an AI Innovation Center, and a Healthcare Industrial Fund to accelerate healthcare transformation in China. The Global R&D Center is responsible for carrying out initiatives for discovery and development of potential new innovative medicines. AI Innovation Center aims to build collaboration with digital startups and technology companies to collaboratively develop AI-based solutions in the areas of operations, R&D, manufacturing, and commercialization.
AstraZeneca operates automation labs, lead discovery center, and accelerator programs in Cambridge.
Automation Labs and Lead Discovery Center: AstraZeneca operates Center for Lead Discovery in Cambridge that focuses on discovering small molecules to develop novel medicines. The center also incorporates advanced screening and compound management facilities. AstraZeneca Center for Lead Discovery collaborated with HighRes Biosolutions, Labcyte, Brooks Automation, and Genedata to leverage automation capabilities in the areas of intelligent robotic screening, liquid compounds handling, liquid compounds storage, and advanced software solutions for drug discovery and data sharing with partners respectively.
AstraZeneca Exchange Accelerator: Launched in 2015, AstraZeneca Exchange event aimed to provide collaboration opportunities to academic institutions and biotech companies operating in the life sciences sector. The platform allows participants to engage in discussions, knowledge-sharing sessions, and form meaningful collaborations to explore solutions addressing key issues faced by the sector.
AstraZeneca’s Boston Bio Hub incubator focuses on supporting emerging startups to advance their biomedical research and develop innovative healthcare solutions. It provides shortlisted companies access to its laboratory facilities and equipment, and mentoring support on legal and business development aspects by experts. The companies shortlisted into AstraZeneca’s Boston Bio Hub incubator include Naveris, Gatehouse Bio, Olaris, and Blue Oak Pharmaceuticals.
This report provides insight into AstraZeneca's digital activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook